<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5711">
  <stage>Registered</stage>
  <submitdate>1/12/2014</submitdate>
  <approvaldate>1/12/2014</approvaldate>
  <nctid>NCT02306291</nctid>
  <trial_identification>
    <studytitle>Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML</studytitle>
    <scientifictitle>A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GMI-1271-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia, Myeloid, Acute</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GMI-1271
Treatment: drugs - GMI-1271
Treatment: drugs - GMI-1271

Experimental: Arm A (Phase I) - GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older

Experimental: Arm B (Phase II Arm A) - GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older

Experimental: Arm C (Phase II Arm B) - GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older


Treatment: drugs: GMI-1271
Dose escalation

Treatment: drugs: GMI-1271
Dose expansion

Treatment: drugs: GMI-1271
Safety run-in then dose expansion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety assessed by frequency, severity and relatedness of adverse events</outcome>
      <timepoint>up to 44 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time versus plasma concentration profile of GMI-1271 - Plasma concentration of GMI-1271</outcome>
      <timepoint>up to 11 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Proportion of subjects who achieve a complete response (CR) or CR with incomplete blood count recovery (CRi) per local investigator assessment</outcome>
      <timepoint>up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to response - Time from date of first dose to first documentation of response</outcome>
      <timepoint>up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response - Time from date of first documented remission to the date of relapse or death from any cause, whichever occurs first</outcome>
      <timepoint>up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event-free survival - Time from date of first dose to the date of treatment failure, relapse, or death from any cause, whichever occurs first</outcome>
      <timepoint>up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - The probability of survival at 6 months (Phase 1) and 12 months (Phase 2), after the date of first dose of study drug</outcome>
      <timepoint>up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. AML (including secondary AML) diagnosed as per WHO criteria

          2. For relapsed/refractory subjects only:

               -  Subjects age = 18 years with relapsed or refractory AML after = 2 prior induction
                  regimens, at least one containing anthracyclines

               -  Medically eligible to receive MEC

               -  Absolute blast count (ABC) = 40,000/mm

          3. For treatment-na√Øve subjects only:

               -  Subjects = 60 years of age with newly diagnosed AML

               -  Medically eligible to receive "7+3" cytarabine/idarubicin

               -  ABC count = 40,000/mm

          4. ECOG performance status 0-2

          5. Hemodynamically stable and adequate organ function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Acute promyelocytic leukemia

          2. Acute leukemia of ambiguous lineage (biphenotypic leukemia)

          3. Active signs or symptoms of CNS involvement by malignancy

          4. No prior G-CSF, GM-CSF or plerixafor within 14 days of study drug dosing

          5. Known history or evidence of active hepatitis A, B, or C or HIV

          6. Uncontrolled acute life threatening bacterial, viral or fungal infection

          7. Active graft versus host disease (GVHD) = Grade 2 or extensive chronic GVHD requiring
             immunosuppressive therapy

          8. Hematopoietic stem cell transplantation = 4 months of dosing

          9. Clinically significant cardiovascular disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>91</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <postcode> - Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Galway</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlycoMimetics Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate GMI-1271, a specific E-selectin antagonist, in acute myeloid
      leukemia in combination with standard agents used to treat this disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02306291</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel DeAngelo, MD, PhD</name>
      <address>Dana-Farber Cancer Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>